title: Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications.
abstract: OBJECTIVE
  Pharmacogenomics investigates interindividual genetic variability in the DNA sequence of drug targets, drug-metabolizing enzymes or disease genes, RNA expression, or protein translation of genes affecting drug response and drug safety. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications with well-documented variation in patient response in terms of efficacy and safety. This variation may in part be explained by pharmacogenomics.
  
  
  METHODS
  In this paper I review data on the pharmacogenomics of aspirin and other NSAIDs focusing on clinical implications.
  
  
  RESULTS
  Existing scientific evidence supports the pharmacogenomic basis of interindividual variation in treatment response to aspirin and NSAIDs, with clinical implications for antiplatelet action, cancer chemoprevention, and drug safety. However, further research efforts are needed before knowledge on the pharmacogenomics of aspirin and NSAIDs can be implemented in clinical practice.
  
  
  CONCLUSIONS
  The outcome of these research efforts would be anticipated to have added value for both science and society, contributing to the enhanced efficacy and safety of these agents through patient selection.
authors: Department of Basic Medical Lessons, Faculty of Health and Caring Professions, Technological Educational Institute of Athens, Eleutheriou Benizelou 106, Kallithea, Athens, 17676, Greece. nyiannak@teiath.gr
authors: Eugenia
authors: E
authors: Yiannakopoulou
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism; D001241:Aspirin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000235:genetics / Q000378:metabolism; D019317:Evidence-Based Medicine; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D057285:Precision Medicine
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010975:Platelet Aggregation Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; D001241:Aspirin